[A18-63] Palbociclib (breast cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Last updated 22.03.2019
Commission awarded on 01.08.2018 by the Federal Joint Committee (G-BA).
Patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer after prior endocrine therapy
PALOMA-3 study unsuitable for the derivation of an added benefit due to inadequate implementation of appropriate comparator therapy; added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A19-14||Palbociclib (breast cancer) - Addendum to Commission A18-63||Commission completed|
|A16-74||Palbociclib (breast cancer) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A22-66||Palbociclib (breast cancer) – Benefit assessment according to § 35a SGB V||Commission completed|